Center for Drug Evaluation and Research(CDER)
CDER is the FDA center responsible for evaluating and regulating prescription and over-the-counter human drugs in the United States.
Usage Examples
- The sponsor requested a Type B meeting with CDER before NDA submission.
- CDER accepted the NDA for filing and issued a PDUFA target action date.
- The team aligned postmarketing commitments with CDER safety expectations.
What is CDER?
The Center for Drug Evaluation and Research (CDER) is one of FDA's major product centers. CDER reviews INDs and NDAs, and oversees many therapeutic biologics regulated under CDER. It evaluates drug safety and effectiveness, monitors postmarket safety, and enforces manufacturing and labeling requirements throughout the product lifecycle.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312, 21 CFR 314, 21 CFR 210.
When This Matters
- The sponsor requested a Type B meeting with CDER before NDA submission.
- CDER accepted the NDA for filing and issued a PDUFA target action date.
- The team aligned postmarketing commitments with CDER safety expectations.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
CDER evaluates human drugs for safety and effectiveness, reviews drug applications, and oversees quality and postmarket safety for products under its jurisdiction.
CDER primarily regulates drugs and many therapeutic biologics, while CBER regulates blood products, vaccines, and certain cell and gene therapies.
Yes. CDER monitors adverse event data, reviews safety signals, and can require label changes or other risk-management actions after approval.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
